{
    "nct_id": "NCT04919226",
    "official_title": "A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin",
    "inclusion_criteria": "* Patients aged â‰¥ 18 years.\n* Histologically confirmed diagnosis of unresectable, well-differentiated GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs). measurable site of disease per RECIST v1.1 (Response evaluation criteria in solid tumors) using contrast computed tomography (CT) / magnetic resonance imaging (MRI).\n* Somatostatin receptor-positive (SSTR+) disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to Lutetium 177Lu, edotreotide, DOTA (dodecane tetraacetic acid), any of the comparators, or any excipient or derivative (e.g. rapamycin).\n* Prior (Peptide Receptor Radionuclide Therapy) PRRT.\n* Any major surgery within 4 weeks prior to randomization in the trial.\n* Therapy with an investigational compound and/or medical device within 30 days or 7 half-life periods (whichever is longer) prior to randomization.\n* Other known malignancies.\n* Serious non-malignant disease.\n* Renal, hepatic, cardiovascular, or hematological organ dysfunction, potentially interfering with the safety of the trial treatments.\n* Pregnant or breastfeeding women.\n* Patients not able to declare meaningful informed consent on their own or any other vulnerable population to that.",
    "miscellaneous_criteria": ""
}